New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.69 2.16 +1.30%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. (GILD) EV/FCF

Alert me on EV/FCF

As of Nov 19, 2026, Gilead Sciences, Inc. (GILD) trades at a EV/FCF of 16.4×. Over the past ten years it has ranged from 5.9× (December 2016) to 22.3× (February 2026); the current reading is higher than 89% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 18.0× 40.45%
FY2024 12.8× (22.70%)
FY2023 16.6× 8.63%
FY2022 15.2× 46.60%
FY2021 10.4× (20.59%)
FY2020 13.1× 30.03%
FY2019 10.1× (5.26%)
FY2018 10.6× 13.99%
FY2017 9.3× 32.44%
FY2016 7.0× (7.46%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 14.9× 6.86%
Jun 2026 13.9× (24.13%)
Mar 2026 18.3× 2.02%
Dec 2025 18.0× 5.88%
43 more quarters

Against its own ten years

Low 5.9× High 22.3×
Ten-year median 11.7×
Current reading's percentile 89

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on GILD